At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Abiraterone acetate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
In Brief
A Phase 2 clinical trial evaluating Abiraterone acetate, Dutasteride, and 1 other intervention for Prostate Cancer. Completed, enrolled 40 participants across 4 sites.
Detailed Summary
The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic disease. This study will also help determine the side effects of the study treatment and how often they occur.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartSep 2011
Primary CompletionJan 2016
Study CompletionMar 2017
TodayJul 2026
First PostedJul 13, 2011
Enrollment StartSep 1, 2011
Primary CompletionJan 1, 2016
Study CompletionMar 15, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.0 years ago
Interventions
Abiraterone acetatedrug
Dutasteridedrug
Prednisonedrug